NCT04400331
Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 15 versions: 15 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Reclassified as terminated (was completed) Sponsor's reason: Sponsor Decision
- Eligibility criteria expanded, about 19 words
- Secondary endpoints: details revised at 1 of 1 entry
- Site details revised at 1 of 34 sites
- Minor Trial status: Active, Not Recruiting to Completed
- Primary and study completion dates changed from estimate of Mar 2026 to Nov 5, 2025
- Minor Site details revised at 1 of 34 sitesv13
- Notable Primary and study completion dates: Dec 2023 to Mar 2026
- Secondary endpoints: details revised at 1 of 1 entry
- Study description expanded, about 45 words
- Minor Trial status: Recruiting to Active, Not Recruiting
- Enrollment target: estimated 150 to confirmed 154
- Site details revised at 34 of 34 sites
Show 9 earlier versionsHide 9 earlier versions
- Notable Eligibility criteria expanded, about 13 words
- Primary and study completion dates: Jul 2023 to Dec 2023
- Secondary endpoints: details revised at 1 of 1 entry
- Minor Study sites: 25 to 34v9
- Notable Eligibility criteria expanded, about 73 words
- Trial status: Enrolling by Invitation to Recruiting
- Enrollment target: 120 to 150
- Study sites: 14 to 25
- Minor Study sites: 13 to 14v7
- Notable Eligibility criteria expanded, about 8 words
- Study sites: 7 to 13
- Minor Study sites: 6 to 7v5
- Minor Study sites: 4 to 6v4
- Minor Study sites: 1 to 4v3
- Notable Eligibility criteria expanded, about 72 words
- Start date changed from estimate of Jul 1, 2020 to Sep 18, 2020
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Number of Participants with Treatment-Emergent Adverse Events (TEAEs)
Timeframe: Up to 262 weeks
Secondary (1)
Change from Baseline in the Unified Huntington's Disease Rating Scale (UHDRS) Total Maximal Chorea (TMC) Score
Arms and interventions
ValbenazineExperimental
Capsule, administered orally once daily.
Drugs: Valbenazine
Sites
34 sites in 2 countries
United States 31, Canada 3